Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07691606 · ClinicalTrials.gov registry record · Phase 1
A Study of ARC-02 in B-cell NHL
A Phase 1 study, sponsored by Taiho Oncology.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
NCT07691606 is a Phase 1 study that is actively recruiting participants, run by Taiho Oncology. The registered enrollment target is 140 participants.
The verdict
NCT07691606, a Phase 1 study, is actively recruiting participants, sponsored by Taiho Oncology.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
Study Summary
This study is to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of ARC-02.
Interventions
- DRUG Rituximab
- DRUG ARC-02
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2026-06-04 |
| Est. Completion | 2030-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07691606
The ClinicalTrials.gov registry entry for NCT07691606 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taiho Oncology, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT07691606 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07691606 about?
NCT07691606 is a clinical study titled "A Study of ARC-02 in B-cell NHL". This study is to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of ARC-02.
What is the current status of trial NCT07691606?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2026-06-04. Estimated completion is 2030-12.
What interventions are being tested in trial NCT07691606?
The interventions under investigation include: Rituximab (DRUG), ARC-02 (DRUG).
Who is sponsoring clinical trial NCT07691606?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.